Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

(2012) J. A. Dumont et al.   BLOOD

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Novel Associations of Multiple Genetic Loci With Plasma Levels of Factor VII, Factor VIII, and von Willebrand Factor

(2010) Nicholas L. Smith et al.   CIRCULATION

Improvements in factor concentrates

(2010) David Lillicrap   CURRENT OPINION IN HEMATOLOGY

Prophylaxis in the haemophilia population

(2010) V. S. BLANCHETTE   HAEMOPHILIA

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology

(2009) Chichi Huang   CURRENT OPINION IN BIOTECHNOLOGY

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

(2009) V. TERRAUBE et al.   HAEMOPHILIA

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A

(2008) N. RISEBROUGH et al.   HAEMOPHILIA